Pfizer Biosimilar Delayed By FDA Warning Letter
Pfizer has disclosed that the U.S. Food and Drug Administration has rejected its proposed biosimilar of blockbuster anemia drugs sold by Amgen and Johnson & Johnson, the latest fallout from an...To view the full article, register now.
Already a subscriber? Click here to view full article